FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Afimkibart

Drug and asset intelligence for Afimkibart with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

Roche →

Recent signals(2)

ClinicalJuly 7, 2026

Phase III Trial of Afimkibart Shows Promise for Moderately to Severely Active Crohn's Disease

A Phase III trial is underway to assess the efficacy and safety of Afimkibart in Crohn's disease patients.

ClinicalJuly 3, 2026

Phase III Trial of Afimkibart Shows Promise for Ulcerative Colitis

A Phase III trial is underway to assess the efficacy and safety of Afimkibart in patients with moderately to severely active ulcerative colitis.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

Roche — Afimkibart

July 7, 2026 · N/A

Topline Data

Roche — Afimkibart

July 3, 2026 · N/A

Indications

Crohn's Disease →

Therapeutic areas

Crohn's Disease →

Gastroenterology →

Gastroenterology · Crohn's Disease →

Gastroenterology · Ulcerative Colitis →

Ulcerative Colitis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.